{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:32:50Z","timestamp":1770485570167,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T00:00:00Z","timestamp":1379030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.clinthera.2013.08.009","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T04:28:48Z","timestamp":1381897728000},"page":"1582-1594.e9","source":"Crossref","is-referenced-by-count":48,"title":["Tolerability and Pharmacokinetics of Delayed-Release Dimethyl Fumarate Administered With and Without Aspirin in Healthy Volunteers"],"prefix":"10.1016","volume":"35","clinical-trial-number":[{"clinical-trial-number":"nct00420212","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00451451","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01281111","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sarah I.","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Nestorov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidy","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginger L.","family":"Milne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H.","family":"Scannevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Novas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine T.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.08.009_bib1","series-title":"[US Prescribing Information]","author":"Tecfidera","year":"2013"},{"key":"10.1016\/j.clinthera.2013.08.009_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2010.09.005","article-title":"Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis","volume":"93","author":"Dutta","year":"2011","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.clinthera.2013.08.009_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00415-004-0348-9","article-title":"The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy","volume":"251","author":"Gilgun-Sherki","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2013.08.009_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.pharmtox.43.100901.140229","article-title":"Regulatory mechanisms controlling gene expression mediated by the antioxidant response element","volume":"43","author":"Nguyen","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2013.08.009_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00204-011-0674-5","article-title":"The cytoprotective role of the Keap1-Nrf2 pathway","volume":"85","author":"Baird","year":"2011","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.clinthera.2013.08.009_bib6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.08.009_bib7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled Phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.08.009_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0090-6980(89)90088-9","article-title":"Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid","volume":"38","author":"Morrow","year":"1989","journal-title":"Prostaglandins"},{"key":"10.1016\/j.clinthera.2013.08.009_bib9","first-page":"615","article-title":"Prostaglandin activity in sustained inflammation of human skin before and after aspirin","volume":"52","author":"Plummer","year":"1977","journal-title":"Clin Sci Mol Med"},{"key":"10.1016\/j.clinthera.2013.08.009_bib10","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/ajcn\/85.5.1185","article-title":"Histamine and histamine intolerance","volume":"85","author":"Maintz","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clinthera.2013.08.009_bib11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12499963","article-title":"Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans","volume":"98","author":"Morrow","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2013.08.009_bib12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.108.141333","article-title":"Niacin-induced \u201cflush\u201d involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model","volume":"327","author":"Papaliodis","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2013.08.009_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/clpt.1991.104","article-title":"Tolerance to nicotinic acid flushing","volume":"50","author":"Stern","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.08.009_bib14","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells","volume":"70","author":"Benyo","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2013.08.009_bib15","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/sj.jid.5700586","article-title":"Langerhans cells release prostaglandin D2 in response to nicotinic acid","volume":"126","author":"Maciejewski-Lenoir","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2013.08.009_bib16","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acid-induced flushing","volume":"115","author":"Benyo","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2013.08.009_bib17","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1172\/JCI42273","article-title":"Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice","volume":"120","author":"Hanson","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2013.08.009_bib18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2008.01739.x","article-title":"Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial","volume":"62","author":"Paolini","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2013.08.009_bib19","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1185\/030079907X199637","article-title":"Validation of a questionnaire to assess niacin-induced cutaneous flushing","volume":"23","author":"Norquist","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2013.08.009_bib20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","article-title":"Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1","volume":"81","author":"Lai","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.08.009_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nprot.2006.375","article-title":"Quantification of F2-isoprostanes as a biomarker of oxidative stress","volume":"2","author":"Milne","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.clinthera.2013.08.009_bib22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/0378-4347(93)80430-C","article-title":"Simplification of the mass spectrometric assay for the major urinary metabolite of prostaglandin D2","volume":"617","author":"Awad","year":"1993","journal-title":"J Chromatogr"},{"key":"10.1016\/j.clinthera.2013.08.009_bib23","unstructured":"Woodworth J, Zhao J, Stecher S, et al. Oral BG-12 in combination with interferon beta-1a or glatiramer acetate: pharmacokinetics, safety and tolerability. Poster P478 presented at: European Committee for Treatment and Research in Multiple Sclerosis [ECTRIMS]; October 13\u201316, 2010; Gothenburg, Sweden."},{"key":"10.1016\/j.clinthera.2013.08.009_bib24","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(08)61619-0","article-title":"Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study","volume":"372","author":"Kappos","year":"2008","journal-title":"Lancet"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813008898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813008898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T21:54:45Z","timestamp":1564523685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813008898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0149291813008898"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.08.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}